MedRegen is focused on developing two drugs.
The lead compound is MRG-001, which has been extensively tested in preclinical models for several indications and has entered phase I/II clinical trials. During the course of 2021, phase 2 clinical trials for several other indications of MRG-001 will be initiated.
MRG-002 is under pre-clinical development for the indication of skin wound healing.
